William McFarland's questions to MariMed Inc (MRMD) leadership • Q2 2024
Question
William McFarland from GDR Research requested additional commentary on the reasons behind the significant disconnect between MariMed's stock price and its reported financial progress.
Answer
CEO Jon Levine expressed strong frustration, describing himself as 'angry' about the market's inefficiency in valuing cannabis stocks. He cited the recent Verano deal as a clear example where a peer sold a fraction of its assets for more than its entire market capitalization, highlighting a sector-wide undervaluation that affects MariMed despite its strong balance sheet, revenue growth, and positive cash flow.